IBI308 is a monoclonal antibody which is under development by Innovent Biologics for the treatment lung cancer, non-Hodgkin lymphoma and other tumor types (Company Pipeline, Innovent Biologics, MAR 20, 2015, View Source;type=IBI308 [SID:1234502443]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!